295 related articles for article (PubMed ID: 17975166)
1. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
Ikeda I; Tomimoto A; Wada K; Fujisawa T; Fujita K; Yonemitsu K; Nozaki Y; Endo H; Takahashi H; Yoneda M; Inamori M; Kubota K; Saito S; Nagashima Y; Nakagama H; Nakajima A
Clin Cancer Res; 2007 Nov; 13(21):6527-31. PubMed ID: 17975166
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
3. 5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model.
Koelink PJ; Robanus-Maandag EC; Devilee P; Hommes DW; Lamers CB; Verspaget HW
Carcinogenesis; 2009 Jul; 30(7):1217-24. PubMed ID: 19420017
[TBL] [Abstract][Full Text] [Related]
4. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
Desreumaux P; Ghosh S
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():2-9. PubMed ID: 16939423
[TBL] [Abstract][Full Text] [Related]
5. DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis.
Nam SY; Kim JS; Kim JM; Lee JY; Kim N; Jung HC; Song IS
Exp Biol Med (Maywood); 2008 Feb; 233(2):180-91. PubMed ID: 18222973
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
Yen EF; Kane SV; Ladabaum U
Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
[TBL] [Abstract][Full Text] [Related]
7. PPARgamma as a new therapeutic target in inflammatory bowel diseases.
Dubuquoy L; Rousseaux C; Thuru X; Peyrin-Biroulet L; Romano O; Chavatte P; Chamaillard M; Desreumaux P
Gut; 2006 Sep; 55(9):1341-9. PubMed ID: 16905700
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis.
Inoue T; Murano M; Abe Y; Morita E; Murano N; Yasumoto S; Toshina K; Nishikawa T; Maemura K; Hirata I; Katsu K
J Gastroenterol Hepatol; 2007 Sep; 22(9):1474-81. PubMed ID: 17716351
[TBL] [Abstract][Full Text] [Related]
9. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice.
Kohno H; Suzuki R; Yasui Y; Miyamoto S; Wakabayashi K; Tanaka T
Clin Cancer Res; 2007 Apr; 13(8):2519-25. PubMed ID: 17438113
[TBL] [Abstract][Full Text] [Related]
11. Will a 5-ASA a day keep the cancer (and dysplasia) away?
Rubin DT; Lashner BA
Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
[TBL] [Abstract][Full Text] [Related]
12. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist.
Linard C; Grémy O; Benderitter M
J Pharmacol Exp Ther; 2008 Mar; 324(3):911-20. PubMed ID: 18077625
[TBL] [Abstract][Full Text] [Related]
13. Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression.
Kim YJ; Lee JS; Hong KS; Chung JW; Kim JH; Hahm KB
Cancer Prev Res (Phila); 2010 Aug; 3(8):963-74. PubMed ID: 20628001
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis.
L'Heureux MC; Brubaker PL
J Pharmacol Exp Ther; 2003 Jul; 306(1):347-54. PubMed ID: 12815012
[TBL] [Abstract][Full Text] [Related]
15. Review article: maintenance therapy in patients with ulcerative colitis.
Orchard T; Probert CS; Keshav S
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():17-22. PubMed ID: 16939425
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment.
Jiang GL; Im WB; Donde Y; Wheeler LA
J Pharmacol Exp Ther; 2010 Dec; 335(3):546-52. PubMed ID: 20833794
[TBL] [Abstract][Full Text] [Related]
17. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions.
Clapper ML; Cooper HS; Chang WC
Acta Pharmacol Sin; 2007 Sep; 28(9):1450-9. PubMed ID: 17723178
[TBL] [Abstract][Full Text] [Related]
18. 5-Aminosalicylic Acid Ameliorates Colitis and Checks Dysbiotic Escherichia coli Expansion by Activating PPAR-γ Signaling in the Intestinal Epithelium.
Cevallos SA; Lee JY; Velazquez EM; Foegeding NJ; Shelton CD; Tiffany CR; Parry BH; Stull-Lane AR; Olsan EE; Savage HP; Nguyen H; Ghanaat SS; Byndloss AJ; Agu IO; Tsolis RM; Byndloss MX; Bäumler AJ
mBio; 2021 Jan; 12(1):. PubMed ID: 33468700
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
González-García A; Sánchez-Ruiz J; Flores JM; Carrera AC
Gastroenterology; 2010 Apr; 138(4):1374-83. PubMed ID: 20004201
[TBL] [Abstract][Full Text] [Related]
20. Increased proliferation of middle to distal colonic cells during colorectal carcinogenesis in experimental murine ulcerative colitis.
Inoue T; Murano M; Kuramoto T; Ishida K; Kawakami K; Abe Y; Morita E; Murano N; Toshina K; Nishikawa T; Maemura K; Shimamoto C; Hirata I; Katsu K; Higuchi K
Oncol Rep; 2007 Dec; 18(6):1457-62. PubMed ID: 17982630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
